| Literature DB >> 25950458 |
Xue-Mei Tan1, Hua Ye1, Kai Yang1, Dan Chen1, Qing-Qing Wang2, Hong Tang1, Ning-Bo Zhao1.
Abstract
Previous studies have suggested that the expression of clock genes have circadian rhythms, and many cell cycle genes are regulated by clock genes. The disruption of circadian rhythms appears to be associated with the acceleration of cancer development. To investigate the circadian patterns of the clock gene Per2 and of cell cycle genes p53, Cyclin D1, CDK1 and Cyclin B1 in different stages of carcinogenesis, the daily mRNA profiles of these genes were detected by real-time RT-PCR in dimethylbenzanthracene-induced cancer, in precancerous lesions and in normal tissues. Per2, p53, Cyclin D1 and CDK1 showed circadian rhythms in the 3 different stages of carcinogenesis, whereas the circadian rhythm of Cyclin B1 was absent in the precancerous lesions. The mesors and amplitudes of Per2 and p53 were decreased (P < 0.05), but the mesors of Cyclin D1, CDK1 and Cyclin B1 were increased with the development of cancer (P < 0.05). Compared with the normal tissues, the acrophases of Per2 and CDK1 were earlier in precancerous lesions, and the acrophases of Cyclin D1, CDK1 and Cyclin B1 occurred later in the cancer cells. Our study represents the first demonstration of the circadian pattern variations of these genes in different stages of carcinogenesis.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25950458 PMCID: PMC4423449 DOI: 10.1038/srep09997
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The golden hamster buccal mucosa model of carcinogenesis:
(A)Photographs of golden hamster buccal mucosa at different stages of carcinogenesis; (B) Pathological slice photos (HE staining, ×400) at different stages of carcinogenesis ( I: normal mucosa, II: precancerous lesion, and III: cancer).
The mRNA expression of Per2, p53, Cyclin D1, CDK1 and Cyclin B1 in groups I, II and III at 6 different time points over 24 h (means ± SD, n = 5).
| Per2 | I | 0.86 ± 0.06 | 0.77 ± 0.10 | 1.89 ± 0.14 | 2.80 ± 0.11 | 1.18 ± 0.09 | 1.54 ± 0.19 | 0.000 |
| II | 0.73 ± 0.18 | 1.33 ± 0.10 | 1.33 ± 0.19 | 1.46 ± 0.24 | 1.12 ± 0.26 | 0.29 ± 0.18 | 0.000 | |
| III | 0.35 ± 0.14 | 1.02 ± 0.13 | 1.13 ± 0.24 | 1.47 ± 0.24 | 1.49 ± 0.25 | 0.35 ± 0.07 | 0.000 | |
| p53 | I | 1.09 ± 0.26 | 1.86 ± 0.27 | 2.64 ± 0.21 | 3.82 ± 0.61 | 4.44 ± 1.40 | 6.20 ± 1.59 | 0.000 |
| II | 2.64 ± 0.63 | 2.06 ± 0.33 | 1.22 ± 0.28 | 2.15 ± 0.20 | 2.63 ± 0.62 | 2.94 ± 1.45 | 0.001 | |
| III | 1.37 ± 0.14 | 0.84 ± 0.03 | 0.71 ± 0.10 | 1.63 ± 0.17 | 1.82 ± 0.69 | 1.40 ± 0.34 | 0.003 | |
| Cyclin D1 | I | 0.86 ± 0.12 | 0.90 ± 0.12 | 1.28 ± 0.37 | 2.51 ± 0.03 | 1.80 ± 1.40 | 1.17 ± 0.40 | 0.000 |
| II | 2.40 ± 0.14 | 1.44 ± 0.29 | 1.36 ± 0.15 | 1.76 ± 0.16 | 2.14 ± 0.19 | 1.67 ± 0.09 | 0.000 | |
| III | 2.38 ± 0.11 | 2.20 ± 0.08 | 2.90 ± 0.16 | 3.19 ± 0.10 | 2.64 ± 0.26 | 2.83 ± 0.24 | 0.000 | |
| CDK1 | I | 5.91 ± 0.95 | 5.10 ± 0.45 | 1.70 ± 0.51 | 2.40 ± 0.44 | 1.21 ± 0.33 | 1.69 ± 0.32 | 0.000 |
| II | 5.39 ± 0.55 | 6.55 ± 0.36 | 1.33 ± 0.11 | 2.08 ± 0.54 | 1.68 ± 0.28 | 10.0 ± 0.82 | 0.000 | |
| III | 2.92 ± 0.49 | 1.68 ± 0.18 | 3.74 ± 0.36 | 6.69 ± 0.48 | 6.36 ± 0.61 | 7.24 ± 0.87 | 0.011 | |
| Cyclin B1 | I | 1.16 ± 0.29 | 1.84 ± 0.12 | 0.39 ± 0.14 | 0.61 ± 0.23 | 1.06 ± 0.10 | 3.00 ± 0.37 | 0.000 |
| II | 1.68 ± 0.27 | 1.92 ± 0.72 | 1.51 ± 0.72w | 2.00 ± 0.25 | 1.70 ± 0.25 | 1.94 ± 0.75 | 0.53 | |
| III | 2.16 ± 0.64 | 1.79 ± 0.15 | 2.14 ± 0.16 | 2.48 ± 0.78 | 4.21 ± 1.00 | 2.55 ± 0.79 | 0.011 |
A value of P < 0.05 represents a significant difference ( I: normal buccal mucosa, II: precancerous lesion, and III: carcinoma; HALO: hour after light onset; SD: standard deviation; n: numbers).
The circadian rhythm characteristics of Per2, p53, Cyclin D1, CDK1 and Cyclin B1 mRNA in groups I, II and III.
| Per2 | I | 1.51 | 0.77 | 16.07 | 2.29 | 0.73 | 0.0009 |
| II | 1.04 | 0.52 | 13.13 | 1.56 | 0.52 | 0.001 | |
| III | 0.96 | 0.58 | 15.53 | 1.53 | 0.38 | 0.0003 | |
| p53 | I | 3.34 | 1.92 | 20.47 | 5.26 | 1.42 | 0.0032 |
| II | 2.33 | 0.86 | 23.87 | 3.19 | 1.47 | 0.007 | |
| III | 1.27 | 0.45 | 21.06 | 1.72 | 0.83 | 0.0021 | |
| Cyclin D1 | I | 1.42 | 0.75 | 17.20 | 2.17 | 0.61 | 0.0001 |
| II | 1.80 | 0.33 | 23.80 | 2.13 | 1.47 | 0.0449 | |
| III | 2.69 | 0.37 | 17.07 | 3.06 | 2.32 | 0.003 | |
| CDK1 | I | 3.00 | 2.14 | 6.11 | 5.14 | 0.86 | 0.0004 |
| II | 4.51 | 3.54 | 2.79 | 8.05 | 0.97 | 0.007 | |
| III | 4.77 | 2.77 | 19.87 | 7.54 | 2.00 | 0.000 | |
| Cyclin B1 | I | 1.35 | 0.91 | 1.66 | 2.26 | 0.44 | 0.0036 |
| II | — | — | — | — | — | 0.9299 | |
| III | 2.55 | 0.93 | 20.13 | 3.48 | 1.62 | 0.0079 |
The circadian rhythm is described by the mesor, amplitude and acrophase. A value of P < 0.05 indicates that the mRNA expression shows a circadian rhythm. (I: normal mucosa, II: precancerous lesion, and III: carcinoma; HALO: hour after light onset).
Figure 2Cosine fitted curves of Per2, P53, Cyclin D1, CDK1 and Cyclin B1 mRNA expression in normal mucosa, precancerous lesions and cancerous tissues.
The solid line in the figure is the cosine fitted curve; the dotted line is the link between the mean values of mRNA expression of each gene at 6 different time points over 24 h.
Primers used for real time PCR amplification of gene expression.
| Per2 | Forward | 5′-AAGCAGGTGAAGGCTAACGA-3′ |
| Reverse | 5′-TCCAGAAACCAGAGACACAGC-3′ | |
| p53 | Forward | 5′-ATGCCGAATACCTGGATGAC-3′ |
| Reverse | 5′-GCGTGATGATGGTGAGGATA-3′ | |
| Cyclin D1 | Forward | 5′-GCCCTCCGTGTCTTACTTCA-3′ |
| Reverse | 5′-CTCTTCGCACTTCTGCTCCT-3′ | |
| CDK1 | Forward | 5′-ATCCTGCCAAACGAATCTCT-3′ |
| Reverse | 5′-GAGCCAACAGTAAATGCCACTA-3′ | |
| Cyclin B1 | Forward | 5′-GGTAACAAAGTCAGCGAGCAG-3′ |
| Reverse | 5′-AGCAAGTTCCACCTCTGGTT-3′ | |
| β-actin | Forward | 5′-GGCAGGCAAAGGTTACTCTG-3′ |
| Reverse | 5′-TGGTGACAGGTGGACAAGAT-3′ |